LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

Actual Patient

LEMTRADA safety and side effects

Understand the potential side effects of LEMTRADA

Safety and side effects information for LEMTRADA

When considering LEMTRADA as your relapsing MS medicine, it's important to discuss potential common and serious side effects with your healthcare provider.

Learn more about the potential side effects of LEMTRADA by clicking and reading through each section below.

SELECTED IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, bleeding disorder (acquired hemophilia A), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions, and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

WHAT ARE THEY?

LEMTRADA can cause serious infusion reactions that may cause death. Serious infusion reactions may happen while you receive, or up to 24 hours or longer after you receive, LEMTRADA.

LEMTRADA should only be administered in certified healthcare settings with on-site equipment and personnel trained to manage infusion reactions, including serious allergic reactions, and urgent heart or breathing problems.

You will be watched while you receive, and for 2 hours or longer after you receive, LEMTRADA. If a serious infusion reaction happens while you are receiving LEMTRADA, your infusion may be stopped.

WHO EXPERIENCED THIS

92%
of patients experienced
infusion reactions in the
LEMTRADA clinical trials
3%
of these reactions
were serious

SYMPTOMS TO WATCH FOR

Tell your healthcare provider right away if you have any of the following symptoms of a serious infusion reaction during the infusion, and after you have left the healthcare facility:

  • swelling in your mouth or throat
  • trouble breathing
  • weakness
  • fast, slow, or irregular heartbeat
  • chest pain
  • rash

PREMEDICATIONS

Corticosteroids

To lower your chances of getting a serious infusion reaction, your healthcare provider will give you a medicine called corticosteroids before your first 3 infusions of a treatment course.

Antihistamines and/or fever reducers

Your healthcare provider may consider administering antihistamines and/or a fever reducer before, during, and after your LEMTRADA infusion.

Infusion reactions can occur despite pretreatment.

OTHER MEDICATIONS

Antivirals

To lower your chances of getting certain serious infections, you’ll be given an antiviral with treatment and will continue taking it under your healthcare provider’s guidance.

Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include:

BLOOD AND BLEEDING DISORDERS
LEMTRADA may cause conditions such as:

  • Immune thrombocytopenic purpura (ITP), a condition of reduced platelet counts in your blood that can cause severe bleeding that leads to life-threatening problems
  • Acquired hemophilia A (AH), an autoimmune disorder characterized by bleeding that occurs in patients with no personal or family history of diseases related to clotting or coagulation
  • Hemophagocytic lymphohistiocytosis (HLH), a rare but potentially fatal condition where overactivity of the immune system causes certain white blood cells to build up and damage organs and destroy other blood cells

KIDNEY PROBLEMS

LEMTRADA may cause kidney problems, such as anti-glomerular basement membrane (anti-GBM) disease, which, if not treated, can lead to severe kidney damage, kidney failure that needs dialysis, a kidney transplant, or death.

LIVER PROBLEMS

Drug-induced autoimmune hepatitis (AIH) can occur when the body’s immune system attacks the liver, causing inflammation. If left untreated, this liver inflammation can eventually cause cirrhosis of the liver, which may lead to liver cancer and liver failure.

THYROID PROBLEMS

Some patients taking LEMTRADA may get an overactive thyroid (hyperthyroidism) or an underactive thyroid (hypothyroidism).

STROKE AND TEARS IN YOUR ARTERIES THAT SUPPLY BLOOD TO YOUR BRAIN

Some people have had serious and sometimes deadly strokes and tears in their carotid or vertebral arteries within 3 days of receiving LEMTRADA. Get help right away if you have any of the following symptoms that may be signs of a stroke or tears in your carotid or vertebral arteries:

  • drooping of parts of your face
  • weakness on one side
  • sudden severe headache
  • difficulty with speech
  • neck pain

CERTAIN CANCERS

Receiving LEMTRADA may increase your chance of getting some kinds of cancers, including:

  • thyroid cancer
  • skin cancer (melanoma)
  • blood cancers called lymphoproliferative disorders and lymphoma

Have your skin checked before you start receiving LEMTRADA and each year while you are receiving treatment to monitor for symptoms of skin cancer.

These are the most common side effects of LEMTRADA:

  • rash
  • headache
  • thyroid problems
  • fever
  • swelling of your nose and throat
  • nausea
  • urinary tract infection
  • feeling tired
  • trouble sleeping
  • upper respiratory infection
  • herpes viral infection
  • hives
  • itching
  • upper respiratory infection
  • herpes viral infection
  • hives
  • itching
  • fungal infection
  • joint pain
  • pain in your arms or legs
  • back pain
  • diarrhea
  • sinus infection
  • mouth pain or sore throat
  • tingling sensation
  • dizziness
  • stomach pain
  • sudden redness in face, neck, or chest
  • vomiting
  • sinus infection
  • mouth pain or sore throat
  • tingling sensation
  • dizziness
  • stomach pain
  • sudden redness in face, neck, or chest
  • vomiting

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of LEMTRADA.

Important Safety Information See More

LEMTRADA can cause serious side effects including serious autoimmune problems. Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include: